More than 31 million Americans are living with eczema/ atopic dermatitis (AD), a chronic inflammatory skin condition that extends far beyond visible symptoms to disrupt sleep, mental health, and daily ...
New Guidance Helps Parents Understand Infant Skin Vulnerability and Bacterial Imbalance A child's eczema severity often ...
Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...
J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...
Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & ...
SaveHealth reports on eczema medications, detailing various options from topical treatments to advanced therapies for ...
MedPage Today on MSN
Assisted Reproduction Linked to Child's Risk of Asthma, Eczema
Children conceived through assisted reproductive technology (ART) were modestly more likely to develop asthma, allergic ...
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...
HealthDay News — Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study published online Nov. 27 in Nutrients.
Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback